Literature DB >> 33283854

CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.

Kanta Horie1, Nicolas R Barthélemy1, Chihiro Sato1, Randall J Bateman1,2,3.   

Abstract

Tau is a microtubule associated protein in the brain that aggregates in Alzheimer's disease to form pathological tangles and neurites. Insoluble tau aggregates composed of the microtubule binding region (MTBR) of tau are highly associated with the cognitive and clinical symptoms of Alzheimer's disease. In contrast, levels of soluble forms of tau, such as CSF total tau and phosphorylated tau-181 and tau-217, increase prior to tau aggregation in Alzheimer's disease, but these biomarkers do not measure the MTBR of tau. Thus, how CSF MTBR-tau is altered in Alzheimer's disease remains unclear. In this study, we used sequential immunoprecipitation and chemical extraction methods followed by mass spectrometry to analyse MTBR-tau species in Alzheimer's disease and control CSF. We quantified MTBR-tau-specific regions in the CSF and identified that species containing the region beginning at residue 243 were the most highly correlated with tau PET and cognitive measures. This finding suggests that CSF level of tau species containing the upstream region of MTBR may reflect changes in tau pathology that occur in Alzheimer's disease and could serve as biomarkers to stage Alzheimer's disease and track the development of tau-directed therapeutics.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; CSF; biomarkers; microtubule binding region; tau

Mesh:

Substances:

Year:  2021        PMID: 33283854      PMCID: PMC7940175          DOI: 10.1093/brain/awaa373

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  45 in total

1.  Caspase-2 cleavage of tau reversibly impairs memory.

Authors:  Xiaohui Zhao; Linda A Kotilinek; Benjamin Smith; Chris Hlynialuk; Kathleen Zahs; Martin Ramsden; James Cleary; Karen H Ashe
Journal:  Nat Med       Date:  2016-10-10       Impact factor: 53.440

2.  Partial volume correction in quantitative amyloid imaging.

Authors:  Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger
Journal:  Neuroimage       Date:  2014-12-05       Impact factor: 6.556

3.  Propagation of tau misfolding from the outside to the inside of a cell.

Authors:  Bess Frost; Rachel L Jacks; Marc I Diamond
Journal:  J Biol Chem       Date:  2009-03-11       Impact factor: 5.157

4.  Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology.

Authors:  Kaj Blennow; Chun Chen; Claudia Cicognola; Kristin R Wildsmith; Paul T Manser; Sandra M Sanabria Bohorquez; Zhentao Zhang; Boer Xie; Junmin Peng; Oskar Hansson; Hlin Kvartsberg; Erik Portelius; Henrik Zetterberg; Tammaryn Lashley; Gunnar Brinkmalm; Geoffrey A Kerchner; Robby M Weimer; Keqiang Ye; Kina Höglund
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

5.  Distinct tau prion strains propagate in cells and mice and define different tauopathies.

Authors:  David W Sanders; Sarah K Kaufman; Sarah L DeVos; Apurwa M Sharma; Hilda Mirbaha; Aimin Li; Scarlett J Barker; Alex C Foley; Julian R Thorpe; Louise C Serpell; Timothy M Miller; Lea T Grinberg; William W Seeley; Marc I Diamond
Journal:  Neuron       Date:  2014-05-22       Impact factor: 17.173

6.  Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

Authors:  Jere E Meredith; Sethu Sankaranarayanan; Valerie Guss; Anthony J Lanzetti; Flora Berisha; Robert J Neely; J Randall Slemmon; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Holly Soares; Michael Ahlijanian; Charles F Albright
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

7.  Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.

Authors:  Jing L Guo; Sneha Narasimhan; Lakshmi Changolkar; Zhuohao He; Anna Stieber; Bin Zhang; Ronald J Gathagan; Michiyo Iba; Jennifer D McBride; John Q Trojanowski; Virginia M Y Lee
Journal:  J Exp Med       Date:  2016-10-17       Impact factor: 14.307

8.  Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau.

Authors:  Jean-Philippe Courade; Rachel Angers; Georges Mairet-Coello; Nathalie Pacico; Kerry Tyson; Daniel Lightwood; Rebecca Munro; David McMillan; Robert Griffin; Terry Baker; Dale Starkie; Ruodan Nan; Marta Westwood; Marie-Laetitia Mushikiwabo; Sophie Jung; Geofrey Odede; Berni Sweeney; Andrew Popplewell; Gillian Burgess; Patrick Downey; Martin Citron
Journal:  Acta Neuropathol       Date:  2018-09-20       Impact factor: 17.088

Review 9.  From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy.

Authors:  Morvane Colin; Simon Dujardin; Susanna Schraen-Maschke; Guy Meno-Tetang; Charles Duyckaerts; Jean-Philippe Courade; Luc Buée
Journal:  Acta Neuropathol       Date:  2019-11-04       Impact factor: 17.088

10.  Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8.

Authors:  Thomas J Malia; Alexey Teplyakov; Robin Ernst; Sheng-Jiun Wu; Eilyn R Lacy; Xuesong Liu; Marc Vandermeeren; Marc Mercken; Jinquan Luo; Raymond W Sweet; Gary L Gilliland
Journal:  Proteins       Date:  2016-02-05
View more
  18 in total

Review 1.  Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment.

Authors:  Nishit Pathak; Sunil Kumar Vimal; Ishi Tandon; Lokesh Agrawal; Cao Hongyi; Sanjib Bhattacharyya
Journal:  Metab Brain Dis       Date:  2021-11-01       Impact factor: 3.584

2.  Rates of longitudinal change in 18 F-flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease.

Authors:  Jeffrey S Phillips; Frederick J Nitchie; Fulvio Da Re; Christopher A Olm; Philip A Cook; Corey T McMillan; David J Irwin; James C Gee; Jacob G Dubroff; Murray Grossman; Ilya M Nasrallah
Journal:  Alzheimers Dement       Date:  2021-09-13       Impact factor: 16.655

3.  Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.

Authors:  Yan Li; Suzanne E Schindler; James G Bollinger; Vitaliy Ovod; Kwasi G Mawuenyega; Michael W Weiner; Leslie M Shaw; Colin L Masters; Christopher J Fowler; John Q Trojanowski; Magdalena Korecka; Ralph N Martins; Shorena Janelidze; Oskar Hansson; Randall J Bateman
Journal:  Neurology       Date:  2021-12-14       Impact factor: 11.800

4.  Untangling the tau microtubule-binding region.

Authors:  Jamie Toombs; Henrik Zetterberg
Journal:  Brain       Date:  2021-03-03       Impact factor: 13.501

5.  Targeted proteolytic products of τ and α-synuclein in neurodegeneration.

Authors:  Yuxing Xia; Grace M Lloyd; Benoit I Giasson
Journal:  Essays Biochem       Date:  2021-12-22       Impact factor: 8.000

6.  Development and validation of a high-sensitivity assay for measuring p217+tau in plasma.

Authors:  Gallen Triana-Baltzer; Setareh Moughadam; Randy Slemmon; Kristof Van Kolen; Clara Theunis; Marc Mercken; Hartmuth C Kolb
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-27

7.  Ultrasensitive tau biosensor cells detect no seeding in Alzheimer's disease CSF.

Authors:  Brian D Hitt; Jaime Vaquer-Alicea; Victor A Manon; Joshua D Beaver; Omar M Kashmer; Jan N Garcia; Marc I Diamond
Journal:  Acta Neuropathol Commun       Date:  2021-05-26       Impact factor: 7.801

Review 8.  Current Status of Clinical Trials on Tau Immunotherapies.

Authors:  Changyi Ji; Einar M Sigurdsson
Journal:  Drugs       Date:  2021-06-08       Impact factor: 11.431

Review 9.  News about the Role of Fluid and Imaging Biomarkers in Neurodegenerative Diseases.

Authors:  Jacopo Meldolesi
Journal:  Biomedicines       Date:  2021-03-04

10.  NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression.

Authors:  David Mengel; Tze How Mok; Akin Nihat; Wen Liu; Robert A Rissman; Douglas Galasko; Henrik Zetterberg; Simon Mead; John Collinge; Dominic M Walsh
Journal:  Cells       Date:  2021-12-13       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.